Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas.
10.3346/jkms.2006.21.4.739
- Author:
Seung Ho YANG
1
;
Moon Kyu KIM
;
Tae Kyu LEE
;
Kwan Sung LEE
;
Sin Soo JEUN
;
Chun Kun PARK
;
Joon Ki KANG
;
Moon Chan KIM
;
Yong Kil HONG
Author Information
1. Department of Neurosurgery, The Catholic University of Korea, Seoul, Korea. hongyk@catholic.ac.kr
- Publication Type:Original Article ; Clinical Trial ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Glioma;
Drug Therapy;
Recurrence;
temozolomide
- MeSH:
Vomiting/chemically induced;
Treatment Outcome;
Survival Analysis;
Neoplasm Recurrence, Local;
Nausea/chemically induced;
Middle Aged;
Male;
Magnetic Resonance Imaging;
Liver Diseases/chemically induced;
Leukopenia/chemically induced;
Humans;
Glioma/*drug therapy/radiotherapy/surgery;
Female;
Drug Administration Schedule;
Dacarbazine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use;
Combined Modality Therapy;
Brain Neoplasms/*drug therapy/radiotherapy/surgery;
Brain/drug effects/pathology;
Antineoplastic Agents, Alkylating/administration & dosage/adverse effects/therapeutic use;
Adult;
Adolescent;
Administration, Oral
- From:Journal of Korean Medical Science
2006;21(4):739-744
- CountryRepublic of Korea
- Language:English
-
Abstract:
Numerous studies have demonstrated the clinical activity of temozolomide, a second-generation alkylating agent, against malignant brain tumors, however, its activity has not been reported in an Asian population. This study analyzed the efficacy and toxicity of temozolomide in 25 adult patients with recurrent or progressive malignant gliomas after surgery and standard radiation therapy with or without chemotherapy, enrolled in our institution since July 2000. Sixteen patients had glioblastoma multiforme (GBM), six with anaplastic astrocytoma, and three with anaplastic oligodendroglioma. Of the 25 patients, 3 (12%) achieved a complete response (CR), 8 (32%) achieved a partial response (PR), 6 (24%) had stable disease (SD), and 8 (32%) had progressive disease (PD). Two patients achieved a CR, 4 patients achieved a PR, 3 patients had SD and 7 patients had PD in GBM, and 1 patient achieved a CR, 4 patients achieved a PR, 3 patients had SD, 1 patient had PD in the non-GBM patients. Median progression free survival was 8 weeks in GBM and 22 weeks in the non-GBM patients. The median overall survival of each group was 17 weeks and 28 weeks. Temozolomide demonstrated moderate activity in recurrent and progressive malignant gliomas without serious toxicity.
